Abstract Submission has been closed. Thank you for your submission.
Abstract submission is available on the online site only.
Presentation style will be either Poster presentation.
We accept abstracts submitted online only through the submission system. You may enter the submission page from "Abstract Submission" button at the bottom of this page.
1.Author information and abstracts must be submitted in English.
2.Abstract title must be up to 120 single-byte characters.
3.Abstract text must be up to 1,200 single-byte characters.
4.The maximum of 6 authors (first author & co-authors) can be registered.
5.Any chart or diagram cannot be included.
6.Special characters are not allowed.
* It is recommended that you prepare your abstract text by Word/ text file in advance, and then copy it on the registration page.
【Abstract Category】
Advance Care Planning
Biology of Symptoms and Treatment Toxicities
Caregiver Support
Communication and Shared Decision Making
End-of-Life Care
Integration and Delivery of Palliative and Supportive Care
Mental Health and Psychological Well-being
Models of Care
Patient Reported Outcomes and Patient Experience
Prevention, Assessment, and Management of Disease and Treatment-related Symptoms
Prognostication
Psychological and Spiritual/Cultural Assessment and Management
Survivorship and Late Effects of Cancer
Other
The presenter (the first author) and the principal investigator must disclose the name of any company or
for-profit organization related to medicine they have a relationship with, defined as follows: in the
following items (3) to (9), (11), (12), exceeding separately stipulated criteria, and (1), (2), (10), (13)
if met. The subject period is from
January 1, 2020 - December 31, 2021from January 1, 2021 - December 31, 2022.
For poster presentation, please prepare and print out the slide, and put it at lower right of the poster
panel.
(1) If your study for this presentation is supported by research funds
(2) If you are or have been an employee of a company and/or a profit-making organization related to medicine
(3) If you have earned >1,000,000 JPY/year as an officer or advisor of a company and/or a profit-making organization related to medicine
(4) If you hold>5% of the stock of a company and/or a profit-making organization related to medicine, or receive dividends >1,000,000 JPY/year
(5) If you have earned >1,000,000 JPY/year as a patent fee from a company and/or a profit-making organization related to medicine
(6) If you have earned >500,000 JPY/year as a lecture fee from a company and/or a profit-making organization related to medicine
(7) If you have earned >500,000 JPY/year as a manuscript fee from a company and/or a profit-making organization related to medicine
(8) If you have research expenses >1,000,000 JPY/year from a company and/or a profit-making organization related to medicine
(9) If you have received >1,000,000 JPY/year as a certain contribution from a company and/or a profit-making organization related to medicine
(10) If you are or have been involved in a certain endowed chair funded by a company and/or a profit-making organization related to medicine
(11) If you have >1,000,000 JPY/year as a fee for expert comment, judgment or testimony in legal proceedings, or others from a company and/or a profit-making organization related to medicine
(12) If you have received remuneration (travel, gifts, or other in-kind payments not directly related to research)equivalent to >50,000 JPY/year from a company and/or a profit-making organization related to medicine
(13) If you are a representative of an organization for clinical study which receives research expenses(donation, contract, others)from a company and/or a profit-making organization related to medicine
In order to review whether your abstract is conformed to the standard of applicable research ethics such
as "GCP", "GPSP", "Ethical guidelines on medical research on humans", "Ethical guidelines on research on
human genome and gene analysis", etc., SCPSC ask you to declare the following items:
The content of your declaration will not affect the acceptance or rejection of your abstract.
Please submit to the following:
□Does your study include medical research on human subjects, human material or human data?
□Does your study comply with the Declaration of Helsinki?
□Was your study approved by an institutional review board before starting the research?
Notification of acceptance or rejection will be announced by email at the end of November, 2022 to the
email address you registered when submitting your abstract.
The detailed information about presentation schedule, such as date and place, is going to be mentioned in
the notification of acceptance.